Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 13.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended upward during the past month.VGM ScoresAt this time, Exelixis has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. It comes with little surprise Exelixis has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.Performance of an Industry PlayerExelixis belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Amgen (AMGN), has gained 5.9% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.Amgen reported revenues of $9.09 billion in the last reported quarter, representing a year-over-year change of +10.9%. EPS of $5.31 for the same period compares with $4.71 a year ago.For the current quarter, Amgen is expected to post earnings of $4.18 per share, indicating a change of +5.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.6% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Amgen. Also, the stock has a VGM Score of B.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks